1. Home
  2. PAII vs ALLO Comparison

PAII vs ALLO Comparison

Compare PAII & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pyrophyte Acquisition Corp. II Class A Ordinary Shares

PAII

Pyrophyte Acquisition Corp. II Class A Ordinary Shares

N/A

Current Price

$10.13

Market Cap

276.8M

Sector

N/A

ML Signal

N/A

Logo Allogene Therapeutics Inc.

ALLO

Allogene Therapeutics Inc.

N/A

Current Price

$2.47

Market Cap

252.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PAII
ALLO
Founded
2025
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
276.8M
252.9M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
PAII
ALLO
Price
$10.13
$2.47
Analyst Decision
Strong Buy
Analyst Count
0
12
Target Price
N/A
$8.27
AVG Volume (30 Days)
54.2K
4.7M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
36.84
EPS
N/A
N/A
Revenue
N/A
$22,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.92
$0.86
52 Week High
$10.17
$2.80

Technical Indicators

Market Signals
Indicator
PAII
ALLO
Relative Strength Index (RSI) 53.42 60.49
Support Level $10.04 $1.01
Resistance Level N/A $2.80
Average True Range (ATR) 0.03 0.18
MACD -0.00 -0.01
Stochastic Oscillator 75.00 57.59

Price Performance

Historical Comparison
PAII
ALLO

About PAII Pyrophyte Acquisition Corp. II Class A Ordinary Shares

Pyrophyte Acquisition Corp II is a special purpose acquisition company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

Share on Social Networks: